: NEWS INDEX
- MVA and Deloitte seminar / 21 September - How to handle intellectual properties efficiently
- BioTech Forum Science Conference - fee reduction for MVA members
- MVA statement to the Danish government's new technology, research and innovation fund
- New groundbreaking collaboration in the Øresund region - Medicon Valley
- Active Biotech and Teva Pharmaceuticals will jointly develop a MS treatment
- Ownership of research results - new report from the Swedish Institute for Growth Policy Studies
- Swegene enters agreement with the research council of Norway
- Danish TopoTarget & Curagen collaborate with the US National Cancer Institute
- North European Life Science United by ScanBalt
: MVA NEWS
MVA and Deloitte seminar: How to handle intellectual properties efficiently
21 September 2004 / Øresundshuset / Copenhagen
Knowledge has become more important for business growth, and companies must focus even more on how to handle intellectual properties efficiently. MVA and Deloitte host a half-day seminar focusing on intellectual properties.
Read more here (in Danish)
BioTech Forum Science Conference - fee reduction for MVA members
Now it's time for Medicon Valley Academy's regional scientific conference!
/Biotechforum_ScienceConference2004.jpg)
Scientific sessions are:
Bioinformatics / Stem Cells / Nanobiotechnology / Proteomics
3D Modelling / Medical Imaging / Drug Development / Biostatistics
Disease Control and Global Epidemics / Food versus Drugs
Point of Care Diagnostics / Neuroscience / The IT Competent Hospital
Medical Devices for Therapy / Diabetes / Inflammation / Cancer
All MVA members get discounted conference fee (Academics fee instead of Industry fee, write 'MVA member' in the box for special remarks)
See the FULL PROGRAM
Register by clicking here
MVA statement to the Danish government's new technology, research and innovation fund
: MEDICON VALLEY NEWS
New groundbreaking collaboration in the Øresund region - Medicon Valley
ACADIA Pharmaceuticals establishes chemical R&D laboratory plant at Medeon Science Park, Malmö.
Read more here (in Swedish)
Active Biotech and Teva Pharmaceuticals will jointly develop a MS treatment
Active Biotech and Teve Pharmaceuticals have been cleared by the U.S. Federal Trade Commission to develop a new drug for multiple sclerosis treatment.
Read more here (in English)
Ownership of research results
New report from the Swedish Institute for Growth Policy Studies.
Read more here (in Swedish)
Swegene enters agreement with the research council of Norway
The Swedish functional genomics consortium SWEGENE and The Research Council of Norway's FUGE programme (Functional Genomics in Norway) recently entered an agreement to encourage collaboration between institutions in the field of functional genomics.
Read more here (in English)
Danish TopoTarget & Curagen collaborate with the US National Cancer Institute for oncology product development
The Danish biotech company TopoTarget recently announced that its licencing partner, CuraGen Corporation has signed a Clinical Trials Agreement with the Division of Cancer Treatment and Diagnosis at the US National Cancer Institute for PXD101, a histone deacetylase (HDAC) inhibitor currently in Phase I clinical trials.
Read more here (in English)
North European Life Science United by ScanBalt
ScanBalt, launched in 2001 by MVA, BioCon Valley in Germany and BioTurku in Finland, has now become an independent not for profit membership based association. The ScanBalt statutes were signed on 25 August 2004 in Turku, Finland, by 22 founding members that represent regions, public institutions and private companies within the life science sector.
Read more here (in English)
: FUTURE EVENTS
Workshop: Molecules in health. From Pre-Clinical Projects to Licensing
28 September 2004 / Odense Universitetshospital / Denmark
bioTEAMsouth invites you to an interactive one-day seminar focusing on challenges in the Scientific, Regulatory and Business Management of Early Clinical Development.
Read more here (in English)
BioBiz Workshop for Start-Up Biotech Companies
9-11 November 2004 / Stockholm / Sweden
Workshop dedicated to scientists considering the creation of new Life Sciences companies and who need support to prepare their business plan. Training in negotiation skills, public speaking, human resources management, company management, etc.
Read more here (in English)
5th Swedish Bioinformatics Workshop
26-27 November 2004 / Lund / Sweden
The workshop programme will consist of twelve PhD student or Postdoc presentations, one Master's student presentation, seminars from three invited speakers and a poster session.
Read more here (in English)
HIV/Aids Conference
8 December 2004 / Copenhagen / Denmark
This international one-day conference will examine the latest drug discovery and drug development discoveries within potential HIV vaccines and the prevention of Aids related diseases in the human body.
Read more here (in English)
: NEW MVA MEMBERS
BioGaia AB - www.biogaia.se - is a Swedish biotechnology company that conducts research, development and manufacturing of probiotic systems that build health in humans and animals. The company sells licenses and products on the international market.
Nordic Vaccine Technology A/S - www.nordic-vaccine.dk - is a vaccine delivery and development company dedicated to the development of efficient and safe vaccines for prophylactic as well as therapeutic use.
Enkam Pharmaceuticals A/S - www.enkam.com - was established in 2000 to develop treatments for CNS disorders as a spin-off from the University of Copenhagen based on more than ten years CNS research of the ENKAM founders.